Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Date:11/5/2008

CALGARY, Nov. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Thursday, November 6, 2008 at 11:00 a.m. MT (1:00 p.m. ET) to update investors on clinical trial results in its U.S. Phase II trial for patients with bone and soft tissue sarcomas metastatic to the lung. The results are scheduled to be presented November 6, 2008 at the Chemotherapy Foundation Symposium XXVI in New York.

To access the conference call by telephone, dial 1-416-915-5651 or 1-800-732-6179. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2471700, or through the Company's website at http://www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at http://www.oncolyticsbiotech.com and will also be available by telephone through November 13, 2008. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 21288636 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release c
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... 29, 2014 Research and Markets  has ... Gas Analyzer, and Gas Chromatograph Market by Type , ... Global Trends & Forecast to 2013 - 2020" ... analyzer is a process analytical instrument that provides chemical ... redefined the way by which companies carry out their ...
(Date:9/29/2014)... NEW YORK , Sept. 29, 2014 /PRNewswire/ ... firm, and The Channel Group ("TCG"), a leader ... transition advisors, have formed an alliance to expand ... to prospective clients. With the alliance, Burnham Securities ... in the scientific, clinical medicine and management in ...
(Date:9/29/2014)... Israel , September 29, 2014 ... novel immunomodulators for severe infections, today announced that the ... has awarded Atox Bio with a contract valued up ... of AB103 to treat Necrotizing Soft Tissue Infections (NSTI) ... threats that end in sepsis. BARDA awarded ...
Breaking Biology Technology:World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2
... IDIX ) announced today that Idenix management will ... Health Care Conference on Monday, May 18, 2009 at 8:40 ... webcast of the company presentation can be accessed under "Calendar ... www.idenix.com . Please log in approximately 5-10 minutes ...
... Trait Will Benefit Everyone from Farmers to Consumers. , ... Wilmington, DE ... reached a regulatory milestone for its next generation of healthier soybean products. ... Canada and the Canadian Food Inspection Agency that its ...
... WHAT: GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, ... company developing human, ... Virus) and other infectious agents to share their strategy for, ... plans to expand preventative trials, currently in, ...
Cached Biology Technology:DuPont Receives Canadian Regulatory Approval for High Oleic Soybean Trait 2DuPont Receives Canadian Regulatory Approval for High Oleic Soybean Trait 3
(Date:9/29/2014)... According to a NASA story from 2009, "human activities in ... fire emissions issue. Palm oil is increasingly grown for use ... fats in processed foods. It has become the most widely ... in recent years to surpass that of soybean oil. , ... has to be cleared to grow the crop, and the ...
(Date:9/29/2014)... get a bad rap, and understandably so. The grain-of-rice-sized ... of millions of acres in the Western U.S. and ... to popular belief, these pests may not be to ... recently swept through the region. Instead, weather and topography ... fires than these bark-boring beetles. , New research led ...
(Date:9/29/2014)... A review article published online in Behavioral Brain ... in the brain as a result of chronic alcohol ... cycle. , Clinical assessments and research indicate that ... disrupted sleep. This can occur when people are actively ... they are abstaining. , "Sleep-wake disturbances can last ...
Breaking Biology News(10 mins):Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... civilian personnel from the U.S. Armed Forces, as well ... and other first-responder personnel from throughout the United States, ... attend the 2009 Force Protection Equipment Demonstration (FPED VII). ... and Marine Corps Base, Quantico, VA, during May 19-21.The ...
... Team Up to Provide High Volume Transaction Solution ... Calif. and NEW YORK, May 11 Communication ... CICI), a leading supplier of electronic signature solutions ... and the recognized leader** in biometric signature verification ...
... EfficiencyWALL, N.J., May 19 BIO-key International, ... in finger-based biometric identification and wireless public ... are deploying BIO-key,s WEB-key(R) biometric identification software ... charging, or eCharging system.(Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
Cached Biology News:Demonstration Features Commercial Technology for Combating Terrorism 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 4Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 5Minnesota Counties Secure New Criminal Charging System With BIO-key(R) Fingerprint Biometrics 2Minnesota Counties Secure New Criminal Charging System With BIO-key(R) Fingerprint Biometrics 3
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Prepared by a modification of the ... Biotechnol. Bioeng., 11 , ... will yield an A 260 ... water (1 cm light path). Physical ...
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
Biology Products: